High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study

Background: : Different treatment strategies can have varying effects on disability and whole brain volume in patients with multiple sclerosis (MS). However, the association between regional brain volume and treatment efficacy is currently unclear. Our objective was to determine whether whole brain volume, as well as the regional volume of cortical and subcortical grey matter, differ with the administration of high-efficacy therapy (HET) versus low-efficacy therapy (LET). Methods: : We evaluated clinical data and change in regional brain volume in 44 patients with relapse-onset MS, who underwent HET (n = 19) or LET (n = 25). Regional brain volume was determined with three-dimensional T1-weighted magnetic resonance imaging using FreeSurfer. The association between volume change and treat-ment type was assessed via generalised linear mixed models (GLMMs). Results: : During the observation period (2.0 +/- 0.16 years), the proportion of patients with a no evidence of disease activity-3'' status was significantly greater in those who underwent HET versus LET (p = 0.012). HET was positively associated with volume changes in the cortex (beta = 0.64, p = 0.0499), left (beta = 0.98, p = 0.0033) and right (beta = 0.77, p = 0.019) caudate and right putamen (beta = 0.87, p = 0.0077), after adjusting for age, sex, and MS severity scores in the GLMMs. Further correction for multiple comparisons by false discovery rate revealed that HET was consistently associated with the volume changes of the left caudate (p = 0.049) and right putamen (p = 0.049). Conclusion: : HET can improve the mid-term prognosis of Japanese patients with relapse-onset MS by reducing disease activity and regional brain volume loss.

Automated summary

The study found that high-efficacy therapy (HET) significantly improves the mid-term prognosis of patients with multiple sclerosis compared to low-efficacy therapy (LET), reducing disease activity and regional brain volume loss.